Epstein Secrets

he correlation between bonds and equities tums higher • High yield keeps climbing despite falling oil prices • Poor liquidity in a crowded trade (Volcker rule and other structural changes) The Japanese had been huge Incremental buyers of US corporate credit this year but last week's data shows this fe

ue to its healthy product mix, solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN gen

e correlation between bonds and equities turns higher • High yield keeps climbing despite falling oi= prices • Poor liquidity in a crowded trade (Volcker r=Ie and other structural changes) The Ja=anese had been huge incremental buyers of US corporate credit this year bu= last week's data shows this fe

ue to its healthy product mix, solid pipe=ine and flexibility to deploy capital to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of

correlation between bonds and equities turns higher • High yield keeps climbing despite falling oil prices • Poor liquidity in a crowded trade (Volcker rule and other structural changes) The Japanese had been huge incremental buyers of US corporate credit this year but last week's data shows this f

due to its healthy product mix, solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN

if the correlation between bonds and equities turns higher High yield keeps climbing despite falling oil prices Poor liquidity in a crowded trade (Volcker rule and other structural changes) The Japanese had been huge incremental buyers of US corporate credit this year but last week's data shows this fe

ue to its healthy product mix, solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN g

if the correlation between bonds and equities turns higher High yield keeps climbing despite falling oil prices Poor liquidity in a crowded trade (Volcker rule and other structural changes) 9 EFTA_R1_01555897 EFTA02454269 The Japanese had been huge incremental buyers of US corporate credit this yea

ue to its healthy product mix, solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN g

if the correlation between bonds and equities turns higher High yield keeps climbing despite falling oil prices Poor liquidity in a crowded trade (Volcker rule and other structural changes) 10 EFTA_R1_00107689 EFTA01785508 The Japanese had been huge incremental buyers of US corporate credit this ye

ue to its healthy product mix, solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN g